10 results on '"Corey Langer"'
Search Results
2. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database
- Author
-
Patrick Bou‐Samra, Austin Chang, Feredun Azari, Gregory Kennedy, Alix Segil, Emily Guo, Melina Marmarelis, Corey Langer, and Sunil Singhal
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2023
3. Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
- Author
-
Jyotsna Natarajan, Nikhil Yegya-Raman, Timothy P. Kegelman, Michael J. Kallan, Leonid Roshkovan, Sharyn Katz, Bonnie Ky, Michael Fradley, Ying Xiao, Sang Ho Lee, Zheng Zhang, Corey Langer, Charu Aggarwal, Roger Cohen, Keith Cengel, William Levin, Abigail T. Berman, and Steven J. Feigenberg
- Subjects
Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2023
4. Long-term Outcomes of Proton Beam Re-irradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer
- Author
-
Abigail Berman, Hann-Hsiang Chao, Charles Simone, Timothy Kegelman, Charu Aggarwal, Joshua Bauml, Aditi Singh, William Levin, Keith Cengel, Steven Feigenberg, Ramesh Rengan, Corey Langer, Christine Ciunci, and John Plastaras
- Subjects
Cancer Research ,Radiation ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2020
5. nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
- Author
-
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel E. Haggstrom, Matei P. Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J. Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W. Goldman, Jared Weiss, on behalf of the ABOUND.70+ Investigators, Ajeet Gajra, Andrei Dobrescu, Bohdan E. Halibey, Corey Langer, Daniel Haggstrom, Eric Anderson, Eugene H. Paschold, Haiying Cheng, Haythem Ali, Hossein Borghaei, Jawad Elias Francis, Ayla Ahmed Kessler, Jen C. Wang, Jonathan Wade Goldman, Jose E. Najera, Nadim F. Nimeh, Joseph Rosales, Konstantin H. Dragnev, Leonardo Forero, Lynne A. Bui, Marc R. Matrana, Maurice Willis, Monika Joshi, Morton Coleman, Moses Sundar Raj, Navkiranjit Gill, Patricia M. Plezia, Manuel R. Modiano, R. Timothy Webb, Rita Axelrod, Robert Andrew Dichmann, Ronald P. Harris, Scott Anthony Sonnier, Vijay Patel, Shaker R. Dakhil, Tarek Mekhail, Thomas Hensing, Tony M. Samaha, Vicky Lee, Kimberly McGregor, William Eyre Lawler, William L. Skinner, and William T. DeRosa
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,lcsh:RC254-282 ,elderly ,law.invention ,nab-paclitaxel ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,randomized trial ,Clinical endpoint ,medicine ,Original Research ,advanced non-small cell lung cancer ,business.industry ,Hazard ratio ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Carboplatin ,Regimen ,030104 developmental biology ,Peripheral neuropathy ,Paclitaxel ,chemistry ,030220 oncology & carcinogenesis ,Relative risk ,carboplatin ,phase 4 ,business - Abstract
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-line nab-paclitaxel days 1, 8, 15 plus carboplatin day 1 of a 21-day cycle (21d) or the same nab-paclitaxel/carboplatin regimen with a 1-week break between cycles (21d + break; 28d). The primary endpoint was the percentage of patients with grade ≥ 2 peripheral neuropathy (PN) or grade ≥ 3 myelosuppression. Other key endpoints included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). A total of 143 patients were randomized (71 to 21d, 72 to 21d + break). The percentage of patients with grade ≥ 2 PN or grade ≥ 3 myelosuppression was similar between the 21d and 21d + break arms (76.5 and 77.1%; P = 0.9258). Treatment exposure was lower in the 21d arm compared with the 21d + break arm. Median OS was 15.2 and 16.2 months [hazard ratio (HR) 0.72, 95% CI 0.44–1.19; P = 0.1966], median PFS was 3.6 and 7.0 months (HR 0.48, 95% CI 0.30–0.76; P
- Published
- 2018
6. Randomized Phase II Trial of Paclitaxel Plus Carboplatin or Gemcitabine Plus Cisplatin in Eastern Cooperative Oncology Group Performance Status 2 Non–Small-Cell Lung Cancer Patients: ECOG 1599
- Author
-
S. Li, Bernardo Leon Rapoport, Corey Langer, William Tester, David H. Johnson, and Joan H. Schiller
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Paclitaxel ,medicine.drug_class ,Deoxycytidine ,Antimetabolite ,Carboplatin ,chemistry.chemical_compound ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Lung cancer ,Aged ,Cisplatin ,Performance status ,business.industry ,Middle Aged ,medicine.disease ,Survival Analysis ,Gemcitabine ,Regimen ,chemistry ,Disease Progression ,Female ,business ,medicine.drug - Abstract
Purpose Appropriate therapy for Eastern Cooperative Oncology Group (ECOG) performance status (PS) -2 patients with advanced non–small-cell lung cancer (NSCLC) remains challenging. PS-2 patients on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall survival (OS) of 19%. Three percent had grade 5 toxicity. Patients and Methods ECOG 1599, the first PS 2–specific, US cooperative group trial for treatment-naïve advanced NSCLC, randomly assigned patients to dose-attenuated carboplatin/paclitaxel (the least toxic regimen in ECOG 1594) or gemcitabine/cisplatin (which yielded an MS of 7.9 months in PS-2 patients). Patients received either carboplatin (area under the concentration-time curve, 6) and paclitaxel 200 mg/m2 every 3 weeks (CbP) or gemcitabine 1 g/m2 days 1 and 8 and cisplatin 60 mg/m2 day 1 every 3 weeks (CG). Results One hundred three patients were enrolled; 100 proved eligible. Median age was 66 years; 46% had at least 5% weight loss; 88% had stage IV or recurrent disease. Median number of cycles administered was three per arm. CbP featured more grade 3 neutropathy (10% v 0%) and more grade ≥ 3 neutropenia (59% v 33%), whereas CG yielded more grade ≥ 3 thrombocytopenia (33% v 14%), more grade ≥ 3 fatigue (22% v 14%), and more grade ≥ 1 creatinine elevations (43% v 6%). One grade 5 toxicity, confined to the CbP arm, occurred. Response rate, time to progression, MS, and 1-year OS rates for CG and CbP, were 23%, 4.8 months, 6.9 months, and 25%, and 14%, 4.2 months, 6.2 months, and 19%, respectively. Conclusion Platinum-based combination chemotherapy for PS-2 patients with NSCLC is feasible with acceptable toxicity, but survival in these patients remains inferior to that of PS-0 to -1 patients.
- Published
- 2007
7. Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline
- Author
-
George Rodrigues, Hak Choy, Jeffrey Bradley, Kenneth E. Rosenzweig, Jeffrey Bogart, Walter J. Curran, Elizabeth Gore, Corey Langer, Alexander V. Louie, Stephen Lutz, Mitchell Machtay, Varun Puri, Maria Werner-Wasik, and Gregory M.M. Videtic
- Subjects
Societies, Scientific ,Consensus ,Lung Neoplasms ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Radiation Oncology ,Humans ,Radiology, Nuclear Medicine and imaging ,Chemoradiotherapy ,Dose Fractionation, Radiation ,Combined Modality Therapy ,United States - Abstract
To provide guidance to physicians and patients with regard to the use of definitive external beam radiation therapy (RT) in locally advanced non-small cell lung cancer (LA NSCLC) based on available medical evidence complemented by consensus-based expert opinion.A panel authorized by the American Society for Radiation Oncology (ASTRO) Board of Directors and Guidelines Subcommittee conducted 3 systematic reviews on the following topics: (1) ideal radical RT dose fractionation for RT alone; (2) ideal radical RT dose fractionation for chemoradiation; and (3) ideal timing of radical radiation therapy with systemic chemotherapy. Practice guideline recommendations were approved using an a priori-defined consensus-building methodology supported by ASTRO and approved tools for the grading of evidence quality and the strength of guideline recommendations.For patients managed by RT alone, a minimum dose of 60 Gy of RT is recommended. Dose escalation beyond 60 Gy in the context of combined modality concurrent chemoradiation has not been found to be associated with any clinical benefits. In the context of combined modality therapy, chemotherapy and radiation should ideally be given concurrently to maximize survival, local control, and disease response rate.A consensus and evidence-based clinical practice guideline for the definitive radiotherapeutic management of LA NSCLC has been created that addresses 3 important questions.
- Published
- 2014
8. [Untitled]
- Author
-
A. Jennifer Fischbach, Corey Langer, Surasak Phuphanich, W.K. Alfred Yung, and Charles Scott
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Anemia ,business.industry ,medicine.medical_treatment ,medicine.disease ,Chemotherapy regimen ,Radiation therapy ,Central nervous system disease ,Neurology ,Tumor progression ,Internal medicine ,Toxicity ,medicine ,Neurology (clinical) ,business ,Anaplastic astrocytoma - Abstract
The Radiation Therapy Oncology Group enrolled 30 patientswith recurrent malignant astrocytomas onto a phase IIstudy (RTOG 91-13). Patients were treated with all-trans-retinoicacid at a starting dose of 120 mg/m2per day orally continuously until disease progression. Fourteenpatients had glioblastoma, 14 had anaplastic astrocytoma, and2 had other histologies; 53% were under 50years of age. All patients had failed radiationtherapy and/or at least one chemotherapy regimen. Allpatients had a Karnofsky performance status score ofat least 70, but only 37% had aKPS of 90-100. Forty percent had a neurologicfunction status of grade 1 (able to work).A minimum of 4 weeks of all-trans-retinoic aciddefined adequate treatment. Twenty-five patients received adequate therapy.Most common toxicities were dry skin, cheilitis, anemia,and headache; 3 patients had grade 3 headacherequiring suspension of all-trans-retinoic acid. No grade 3hematologic toxicity was observed. Of 25 adequately treatedpatients, 3 showed objective regression of tumor onmagnetic resonance imaging and computed tomography scans, 3patients remained stable, and 19 patients had diseaseprogression. The median time to tumor progression was3.8 months and the median survival time was5.7 months.This study suggests that this dose of singleagent all-trans-retinoic acid has modest clinical activity againstrecurrent malignant gliomas with tolerable side effects. Aresponse rate of 12% and a stabilization rateof 12% are lower than expected. Future studieswith higher dosage or in combination with biologicalresponse modifiers or chemotherapy may be warranted.
- Published
- 1997
9. Lung cancer in the elderly
- Author
-
P. Maione, Antonio Rossi, Cesare Gridelli, Corey Langer, and Steven E. Schild
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Population ,Antineoplastic Agents ,Comorbidity ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Combined Modality Therapy ,Humans ,education ,Lung cancer ,Aged ,education.field_of_study ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,Patient Selection ,Combination chemotherapy ,medicine.disease ,humanities ,Surgery ,Radiation therapy ,Chemotherapy, Adjuvant ,Radiotherapy, Adjuvant ,business ,Chemoradiotherapy - Abstract
Purpose Elderly patients often have comorbidities and other characteristics that make the selection of treatment daunting. Methods We have reviewed the available evidence in the literature to gauge the results of therapy for elderly lung cancer patients. Results The beneficial results achieved with adjuvant chemotherapy in the general population with early non–small-cell lung cancer (NSCLC) cannot be automatically extrapolated to the elderly, who are at higher risk of toxicity. Retrospective analyses of combined chemoradiotherapy in locally advanced NSCLC patients suggest equivalent therapeutic benefit for younger and older patients, despite heightened toxicity. There have been no elderly-specific phase III trials for locally advanced NSCLC. For advanced NSCLC, on the basis of evidence-based data, single-agent chemotherapy remains the standard of care for nonselected elderly patients. However, retrospective analyses suggest that the efficacy of platinum-based combination chemotherapy is similar in fit older and younger patients, with increased but acceptable toxicity for elderly patients. In limited-disease small-cell lung cancer (SCLC), sequential chemoradiotherapy is clearly less toxic compared with a standard concurrent approach, but our assessment of treatment is hindered by the absence of prospective elderly-specific trials. Although prophylactic cranial irradiation has emerged as a standard strategy, it should be omitted in patients with cognitive impairment. In extensive SCLC, etoposide in combination with either cisplatin or carboplatin has emerged as standard treatment; hematopoietic support may be necessary. Conclusion With the exception of advanced NSCLC, prospective elderly-specific studies are lacking. Available data suggest that outcomes in the fit elderly mirror results observed in younger patients, although toxicity is generally worse.
- Published
- 2007
10. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
- Author
-
Benjamin Wang, Troy H. Guthrie, Nasser H. Hanna, Paul A. Bunn, Corey Langer, Thaddeus Beck, Rafat Ansari, Alan B. Sandler, Lawrence H. Einhorn, Mark E. Morrison, Subramanian Hariharan, Peter M. Ellis, and Michael Byrne
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Neutropenia ,Irinotecan ,Gastroenterology ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Extensive stage ,Carcinoma, Small Cell ,Lung cancer ,Etoposide ,Aged ,Neoplasm Staging ,Cisplatin ,Aged, 80 and over ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Camptothecin ,Female ,business ,Febrile neutropenia ,Progressive disease ,medicine.drug - Abstract
Purpose Etoposide and cisplatin (EP) has been a standard treatment for extensive-disease small-cell lung cancer (SCLC). An earlier phase III trial reported improved survival for patients receiving irinotecan plus cisplatin (IP) versus EP. Our trial was designed to determine if a modified weekly regimen of IP would provide superior survival with less toxicity than EP. Patients and Methods The primary objective was to compare overall survival in extensive-disease SCLC patients randomly assigned to receive IP (n = 221) or EP (n = 110). Patients were randomly assigned in 2:1 ratio to cisplatin 30 mg/m2 intravenously (IV) + irinotecan 65 mg/m2 IV on days 1 and 8 every 21 days, or cisplatin 60 mg/m2 IV on day 1, and etoposide 120 mg/m2 IV on days 1 to 3 every 21 days for at least four cycles, until progressive disease, or until intolerable toxicity resulted. Results Selected grade 3/4 toxicities for IP/EP were: neutropenia (36.2% v 86.5%; P < .01), febrile neutropenia (3.7% v 10.4%; P = .06), anemia (4.8% v 11.5%; P = .02), thrombocytopenia (4.3% v 19.2%; P < .01), vomiting (12.5% v 3.8%; P = .04), and diarrhea (21.3% v 0%; P < .01). There was no significant difference in response rates (48% v 43.6%), median time to progression (4.1 v 4.6 months), or overall survival (median survival time, 9.3 months v 10.2 months; P = .74). Conclusion Treatment with this dose and schedule of IP did not result in improved survival when compared with EP. Fewer patients receiving IP had grade 3/4 anemia, thrombocytopenia, neutropenia, and febrile neutropenia compared with patients receiving EP, but more had grade 3/4 diarrhea and vomiting.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.